Korea's Cancer Survival Rates, 2026: What Do the Real Numbers Show?

Cancer survival rates in Korea vary widely by cancer type. The overall 5-year relative survival rate across all cancers combined is 73.7% (National Cancer Registration Statistics, 2019-2023). This is a nationwide figure, not the performance record of any single hospital.

Key Takeaways

• Korea's overall 5-year relative survival rate for all cancers combined is 73.7% (National Cancer Registration Statistics 2019-2023, National Cancer Center Korea).
• Rates differ widely by cancer type: thyroid cancer 100.2%, prostate cancer 96.9%, breast cancer 94.7%, stomach cancer 78.6%, and leukemia 55.7% (National Cancer Registration Statistics 2019-2023).
• These figures are nationwide statistics. Under Korean medical law, individual hospitals are not permitted to advertise their own outcome data, so these numbers cannot be read as the results of any specific institution.
• A large part of the difference in survival rates comes not only from treatment technology but from how early cancers are detected. For example, Korea offers national screening every two years starting at age 40, including gastroscopy and mammography.
• Survival rates are population averages, not predictions for any individual. Actual outcomes vary person to person depending on stage at diagnosis and overall health status.

What Is Korea's Overall Cancer Incidence Rate?

• This note confirms survival rates and the number of diagnoses by cancer type, but the source material does not include a specific figure for overall incidence (the raw number of new cases relative to population). For reference, in 2023 alone, more than 35,000 thyroid cancer cases and roughly 30,000 breast cancer cases were diagnosed (National Cancer Registration Statistics).
• Thyroid cancer is cited as the most commonly diagnosed cancer in Korea largely because ultrasound screening is widespread, leading to detection even of very small tumors.
• A high number of diagnoses does not necessarily mean a cancer is dangerous. Some cancers, like thyroid cancer, generally have a favorable course, while others, such as blood cancers, can vary greatly in outcome depending on subtype.

How Does This Compare with Other Countries, Such as the United States?

• For stomach cancer, Korea's rate of 78.6% is far higher than the US (SEER 2016-2022) rate of 39.8%. For prostate cancer, Korea's 96.9% is similar to or slightly lower than the US's 98.2%. For breast cancer, Korea's 94.7% is somewhat higher than the US's 91.9%.
• For leukemia, Korea's rate is 55.7% versus 68.6% in the US, but direct comparison is difficult because the two countries differ in the proportion of acute versus chronic cases and in the age distribution of patients at diagnosis.
• Which country shows a higher rate depends on the cancer type, and this reflects not just differences in treatment quality but also national screening systems, the distribution of stage at diagnosis, and population composition. A country's statistics cannot be directly translated into an individual patient's expected treatment outcome.

Can These Survival Rates Tell Me Which Hospital Is Best?

• No, they cannot. Korean medical law restricts recruitment agents and others from advertising specific healthcare providers or institutions, so publicly available data does not disclose hospital names or hospital-specific outcomes.
• All figures presented here are nationwide averages compiled through the National Cancer Registration Statistics, not numbers that promise a particular individual's treatment outcome. Actual results vary greatly depending on stage, histologic type, age, and coexisting conditions.
• One option is to compare hospitals suited to your cancer type, stage, budget, and language needs, and receive guidance through a written opinion. However, the final choice of hospital and specific treatment plan should be determined through consultation with your treating medical team.

FAQ — Why Is There Such a Large Difference in Survival Rates Between Cancer Types?

This is because cancer types differ in how quickly they progress, how easily they can be caught early, and how well they respond to treatment. For example, thyroid cancer (100.2%) and prostate cancer (96.9%) tend to progress slowly and are often caught early, whereas leukemia (55.7%) is a blood cancer whose course can vary dramatically depending on subtype and risk group. For these reasons, even though they are all called 'cancer,' they cannot be compared using the same survival-rate figure (National Cancer Registration Statistics 2019-2023).

FAQ — What Time Period Does This Data Cover, and How Current Is It?

The figures presented are based on National Cancer Registration Statistics for 2019-2023, compiled by the National Cancer Center Korea's Central Cancer Registry. For prostate cancer specifically, a long-term trend is also noted: a 37.7 percentage point increase compared to patients diagnosed in 1993-1995, which is attributed to wider use of PSA testing leading to a higher proportion of localized-stage diagnoses.

Sources and Notes

• This article was written based on National Cancer Registration Statistics 2019-2023 (National Cancer Center Korea, Central Cancer Registry), SEER (US National Cancer Institute), and frequently asked question notes.
• This content is intended for general medical information purposes only. Diagnosis, treatment methods, and outcomes may vary depending on individual circumstances. Please consult your medical team to determine an accurate diagnosis and treatment plan.